|
沙发
楼主 |
发表于 2015-9-17 11:13:59
|
只看该作者
rojjer发表于 2008-5-23 21:18 :
GSK公司用于预防致命性H5N1流感病毒的疫苗Prepandrix通过欧盟委员会批准。此前不久,该药在今年2月份也刚获得欧盟委员会的推荐。GSK是首家在欧洲获得禽流感疫苗许可的制药商。
Prepandrix通过增强人体免疫系统功能而起作用,使人体对H5N1病毒产生抵抗力。目前,已有100人死于禽流感,还导致数以百万计的家禽死亡。
多个欧洲国家,如瑞士和芬兰等已安排订购这种疫苗,同时也联系GSK商讨库存问题。除了GSK,塞诺菲-安万特、诺华和Baxter等多家知名制药企业也正在研发这类疫苗。
The European Medicines Agency today recommended the authorisation of the first ‘pre-pandemic vaccine’ for humans against influenza caused by the H5N1 virus. This is an avian influenza (‘bird flu’) virus strain that has the potential to evolve into a pandemic influenza virus affecting humans.
Prepandrix, from GlaxoSmithKline Biologicals, is a pre-pandemic vaccine that is intended to trigger an immune response against the H5N1 strain of the influenza virus before or during an officially declared influenza pandemic, in accordance with official guidance.
An influenza pandemic is a global outbreak of influenza that leads to serious illness in large numbers of people. It is caused by an influenza virus strain against which most or all humans have no natural protection, and which has mutated into a form that spreads easily from person to person. Health authorities are concerned that the next pandemic could occur at some point within the next few years and could be caused by the H5N1 strain.
The EMEA recommendation has been sent to the European Commission for the adoption of a marketing authorisation decision. |
|